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Heat-shock proteins act as molecular chaperones to pro-tect their substrates or client proteins from degradation in 
conditions of cellular stress, such as hypoxia, oxidative stress, 
and heat.1 Heat-shock protein 90 (Hsp90) is expressed at 
increased levels in many cancers and promotes tumor growth 
and metastasis by stabilizing proteins necessary for tumor 
survival. Several well-known drivers of lung cancer tumori-
genesis, such as epidermal growth factor receptor (EGFR), 
anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma 
viral oncogene homolog B1, mesenchymal epithelial transi-
tion factor, human epidermal growth factor receptor 2 are 
all client proteins of Hsp90. Hsp90 inhibitors have promis-
ing activity in non–small-cell lung cancer (NSCLC) and were 
discussed at the Targeted Therapies Meeting in Santa Monica, 
2012, in a dedicated session.
SUMMARY OF PRESENTATIONS
Dr. Sequist presented an overview of the Hsp90 path-
way and its critical role in cancer cell survival in supporting 
oncoproteins and overcoming cellular stress. Hsp90 can buf-
fer cancer cells from environmental stressors by promoting 
stability of survival pathways involved in sustaining angiogen-
esis, evading host immune response, promoting growth-factor 
independent growth, reprogramming cellular metabolism, and 
avoiding apoptosis. Dr. Sequist also reviewed preclinical data 
demonstrating the sensitivity of ALK positive NSCLC cells to 
Hsp90 inhibition, even in the setting of crizotinib resistance. 
Her discussion summarized the critical role of Hsp90 in cel-
lular function and the rationale for its emergence as a rational 
target for the treatment of NSCLC.
STA-9090 (GANETESPIB)
Dr. Ramalingam described the development of gane-
tespib, a non-geldanamycin Hsp90 inhibitor that has demon-
strated promising anticancer activity in early-phase clinical 
trials. This agent is associated with minimal hepatic and ocu-
lar toxicity, probably because of its unique structure when 
compared with older Hsp90 inhibitors. In a phase II study of 
ganetespib administered to previously treated stage IIIB/IV 
NSCLC,2 tumor genotyping was performed to stratify patients 
into subgroups with EGFR mutations, K-RAS mutations, 
and wild type for both. Echinoderm microtubule-associated 
protein-like 4-ALK testing was subsequently introduced after 
the study was initiated. Ganetespib was tolerated well, with 
diarrhea being the most frequently encountered adverse event 
(AE). Disease stabilization was achieved in several patients 
with EGFR and K-RAS mutation. However, all four patients 
who achieved objective response, including one patient with 
a complete response, had ALK rearrangements. This observa-
tion is supported by the fact that in vitro data have confirmed 
the activity of ganetespib in ALK positive cancer cell lines.
On the basis of its promising single-agent activity, 
combination studies of ganetespib are currently underway. 
A phase I study of ganetespib in combination with docetaxel 
has recently been completed. The recommended phase II dose 
for the combination is ganetespib 150 mg/m2 on days 1 and 
15 with docetaxel 75 mg/m2 on a 21-day cycle. The common 
AEs seen were grade 4 neutropenia, diarrhea, anemia, fatigue, 
and febrile neutropenia.3 Promising efficacy was noted in a 
refractory patient population and has now led to a randomized 
study of docetaxel alone or in combination with ganetespib for 
second-line therapy of advanced NSCLC (GALAXY study–
Ganetespib Assessment in Lung cAncer with docetaXel). This 
study is currently enrolling patients with an estimated sample 
size of 240 patients for the phase II part.
AUY-922
Dr. Riely discussed another novel isoxazole Hsp90 
inhibitor, AUY-922. A phase I study of this agent has been 
completed for patients with advanced solid organs and the 
results were reported at the annual American Society of 
Clinical Oncology meeting in 2010.4 Among the patients 
included in this study, nine had NSCLC; the maximum toler-
ated dose was 70 mg/m2 intravenously once a week, with the 
most common toxicities being fatigue, diarrhea, and vision 
changes consisting of night blindness. A dose-related induc-
tion of Hsp70 was seen in post-treatment tissue, which indi-
cates inhibition of Hsp90. An ongoing phase II study using 
AUY-922 in the third-line setting in patients with advanced 
NSCLC stratifies patients into molecular subgroups, based 
on mutations in EGFR, K-RAS, and ALK rearrangement. 
Another study is enrolling EGFR-mutated NSCLC patients 
with acquired resistance to erlotinib, to examine AUY-922 in 
combination with erlotinib.
DS-2248
Dr. Govindan discussed a new orally available Hsp90 
inhibitor, DS-2248, developed by Daiichi Sankyo (Tokyo, 
Japan). This compound is being studied in a phase I trial at 
Wayne State University and South Texas Accelerated Research 
Therapeutics.5 The trial has a two-part design, with an initial 
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standard dose-escalation study in patients with advanced solid 
tumors, to determine a maximum tolerated dose. Once a rec-
ommended phase II dose (RP2D) is determined, the second 
part of the study will enroll patients with advanced NSCLC 
with resistance to EGFR inhibitors, erlotinib and gefitinib. The 
primary endpoint will be objective response rate with second-
ary endpoints including progression-free survival, pharmaco-
kinetics, disease-control rate, response duration, and duration 
of stable disease.
IPI-504 (RETASPIMYCIN)
Dr. Heist concluded the session with a review of 
retaspimycin, another geldanamycin Hsp90 inhibitor. In a 
phase II study of IPI-504 in advanced NSCLC previously 
treated with EGFR inhibitors, an overall response rate of 7% 
was observed.6 Interestingly, two of three patients with ALK 
rearrangement had partial responses, and all three patients 
continued therapy for at least 7 months. These results were 
the first to suggest that ALK positive NSCLC may repre-
sent a particularly sensitive subgroup of NSCLC to Hsp90 
inhibition.
In preclinical studies, the combination of retaspimycin 
with rapamycin has shown promising activity in mouse tumor 
xenograft models of K-RAS mutated NSCLC with p53 defi-
ciency.7 On the basis of these findings, a phase Ib/II study is 
underway to examine the efficacy of IPI-504 in combination 
with everolimus, an mammalian target of rapamycin inhibitor, 
in NSCLC patients with K-RAS mutations. Once the recom-
mended phase II dose is determined, the primary endpoint of 
the trial will be response rate.
At last year’s annual meeting of the American Society of 
Clinical Oncology, Riely et al.8 reported the results of a phase 
Ib trial of retaspimycin with docetaxel in previously treated 
NSCLC. The most commonly reported AEs were fatigue, 
gastrointestinal toxicities, and anemia. Six of the 23 enrolled 
patients achieved partial responses; the objective response rate 
was 43% in squamous cell carcinoma, 36% in K-RAS wild 
type, and 33% in smokers. This drug will be studied further in 
a phase II trial of advanced NSCLC patients selected for pre-
viously treated smokers who will be randomized to docetaxel 
with retaspimycin or docetaxel alone. The primary endpoint 
will be overall survival.
FUTURE DIRECTIONS
Hsp90 inhibitors have demonstrated efficacy in patients 
with advanced NSCLC. The results reported from the initial 
studies with these agents show that Hsp90 inhibition seems 
to benefit specific molecular subgroups of NSCLC patients. 
Further studies are needed to confirm these observations in 
larger cohorts of patients and to identify additional sensitive 
subsets of patients. The combination of Hsp90 inhibition with 
conventional chemotherapy like docetaxel is well tolerated 
and will be explored further for efficacy in phase II studies. 
Using Hsp90 inhibitors concomitantly with targeted thera-
pies against driver mutations in NSCLC, such as with EGFR 
tyrosine kinase inhibitors or with crizotinib in ALK-mutated 
NSCLC, may also become a strategy to overcome treatment 
resistance in the near future.
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